Dr. Bordonaro on the Treatment of Advanced CRC

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Bordonaro says the only choice for patients who have RAS wild-type disease and fail on oxaliplatin- and irinotecan-based chemotherapy is panitumumab. However, this therapy cannot be used if the patient received panitumumab plus oxaliplatin-based chemotherapy in the first-line setting.

The only option for patients who have received prior panitumumab therapy is regorafenib, Bordonaro says. This recomendation is based on the recent data of the CORRECT trial, a phase III study that tested the efficacy of regorafenib in comparison to placebo in patients in the third-line.